Targeting the HER-kinase axis in cancer

被引:58
作者
Gross, ME [1 ]
Shazer, RL [1 ]
Agus, DB [1 ]
机构
[1] Cedars Sinai Med Ctr, Louis Warschaw Prostate canc ctr, Los Angeles, CA 90048 USA
关键词
D O I
10.1053/j.seminoncol.2004.01.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases controls critical pathways involved in the differentiation, growth, division, and motility of normal epithelial cells. Most human solid tumors are of epithelial origin. The process of malignant transformation and progression in many cancers may depend on activation of ligands and receptors that function as part of the HER-kinase pathway. This signaling axis has earned increased attention because of the development of antibodies and small-molecule tyrosine kinase inhibitors that specifically target components of the HER-kinase axis for cancer therapy. This review focuses on the basic biology underlying HER-kinase pathway activation and the current state of development for agents that target this axis. In particular, the importance of pan-HER inhibitors is discussed. © 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 108 条
  • [91] EPIDERMAL GROWTH-FACTOR, ESTROGEN AND PROGESTERONE-RECEPTOR EXPRESSION IN PRIMARY OVARIAN-CANCER - CORRELATION WITH CLINICAL OUTCOME AND RESPONSE TO CHEMOTHERAPY
    SCAMBIA, G
    BENEDETTIPANICI, P
    FERRANDINA, G
    DISTEFANO, M
    SALERNO, G
    ROMANINI, ME
    FAGOTTI, A
    MANCUSO, S
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 361 - 366
  • [92] THE DRUG RESISTANCE-RELATED PROTEIN LRP IS THE HUMAN MAJOR VAULT PROTEIN
    SCHEFFER, GL
    WIJNGAARD, PLJ
    FLENS, MJ
    IZQUIERDO, MA
    SLOVAK, ML
    PINEDO, HM
    MEIJER, CJLM
    CLEVERS, HC
    SCHEPER, RJ
    [J]. NATURE MEDICINE, 1995, 1 (06) : 578 - 582
  • [93] SCHILLER J, 2003, P AN M AM SOC CLIN, V22, P648
  • [94] The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma
    Skirnisdóttir, I
    Sorbe, B
    Seidal, T
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 (02) : 119 - 129
  • [95] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon, DJ
    Leyland-Jones, B
    Shak, S
    Fuchs, H
    Paton, V
    Bajamonde, A
    Fleming, T
    Eiermann, W
    Wolter, J
    Pegram, M
    Baselga, J
    Norton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 783 - 792
  • [96] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE
    SLAMON, DJ
    CLARK, GM
    WONG, SG
    LEVIN, WJ
    ULLRICH, A
    MCGUIRE, WL
    [J]. SCIENCE, 1987, 235 (4785) : 177 - 182
  • [97] Tyrosine kinase inhibitors.: 15.: 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
    Smaill, JB
    Palmer, BD
    Rewcastle, GW
    Denny, WA
    McNamara, DJ
    Dobrusin, EM
    Bridges, AJ
    Zhou, HR
    Showalter, HDH
    Winters, RT
    Leopold, WR
    Fry, DW
    Nelson, JM
    Slintak, V
    Elliot, WL
    Roberts, BJ
    Vincent, PW
    Patmore, SJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (10) : 1803 - 1815
  • [98] TABERNERO J, 2003, P AN M AM SOC CLIN, V22, P192
  • [99] Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer
    Türkeri, LN
    Erton, ML
    Çevik, I
    Akdas, A
    [J]. UROLOGY, 1998, 51 (04) : 645 - 649
  • [100] Bivalence of EGF-like ligands drives the ErbB signaling network
    Tzahar, E
    PinkasKramarski, R
    Moyer, JD
    Kapper, LN
    Alroy, I
    Levkowitz, G
    Shelly, M
    Henis, S
    Eisenstein, M
    Ratzkin, BJ
    Sela, M
    Andrews, GC
    Yarden, Y
    [J]. EMBO JOURNAL, 1997, 16 (16) : 4938 - 4950